Compare SLAB & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLAB | RYTM |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.8B |
| IPO Year | 2000 | 2017 |
| Metric | SLAB | RYTM |
|---|---|---|
| Price | $218.01 | $107.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $163.13 | $131.14 |
| AVG Volume (30 Days) | 345.6K | ★ 765.9K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.61 | 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $491,625,000.00 | N/A |
| Revenue This Year | $20.49 | $55.34 |
| Revenue Next Year | $16.65 | $86.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $115.51 | $62.29 |
| 52 Week High | $220.90 | $122.20 |
| Indicator | SLAB | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 74.97 |
| Support Level | $217.03 | $97.65 |
| Resistance Level | $219.18 | $113.03 |
| Average True Range (ATR) | 1.58 | 4.92 |
| MACD | -0.22 | 2.17 |
| Stochastic Oscillator | 24.58 | 84.20 |
Silicon Laboratories Inc Inc is a provider of secure, intelligent wireless technology for a more connected world. The company's integrated hardware and software platform, intuitive development tools, industry ecosystem, and robust support help customers build industrial, commercial, home, and life applications. Company make it easy for developers to solve complex wireless challenges throughout the product lifecycle and get to market quickly with solutions that transform industries, grow economies, and improve lives. Company operates in USA, China, Taiwan and Rest of World, with maximum revenue from rest of the world.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.